One platform for all researcher needs
AI-powered academic writing assistant
Your #1 AI companion for literature search
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage All Access membership.
Explore Editage All Access
Open Accesshttps://doi.org/10.1182/blood-2020-137279
Copy DOI Journal: Blood |  Publication Date: Nov 5, 2020 |
 Citations: 2 |
Affiliation: Mayo Clinic, Gartnavel General Hospital, Centre Hospitalier Universitaire de Nîmes, University of Florence, Republic Klaipeda Hospital, Institut Gustave Roussy, University of Milan, National University Cancer Institute, Singapore, Bristol-Myers Squibb (United States), St Thomas' HospitalFedratinib, an Oral, Selective Inhibitor of Janus Kinase 2 (JAK2), in Patients with Intermediate-2 or High-Risk Myelofibrosis (MF): Updated Results from the Randomized, Placebo-Controlled, Phase III JAKARTA Trial
Sign-in/Register to access full text options 
Free) Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
